Antirejection medicines, also known as immunosuppressive drugs, are prescribed to organ transplant recipients to prevent their bodies from rejecting the new organ. Some organ transplant recipients can stop taking anti-rejection medicines without rejecting their transplanted organ (this is called 'tolerance'). The purpose of this study will collect samples and data from 'tolerant' liver or kidney transplant recipients in order to find out: The purpose of this study is to collect samples and data in order to find out: - How long liver or kidney transplant recipients can remain tolerant; - What happens in the tolerant recipient's body over time; and - If there are patterns in the body that are linked to tolerance.
A Prospective Cohort Study of Operationally Tolerant Allograft Recipients (ITN063ST)
Kidney TransplantLiver Transplantsingle organ liver or kidney allograftoperationally tolerant allograft recipientslongitudinal follow-up
You can join if…
Recipient of single organ liver or kidney allograft from a living or deceased donor;
At screening, operationally tolerant, as defined by:
Absence of any immunosuppressive therapy for>= 52 weeks prior to the screening visit
No evidence of allograft rejection in the 52 weeks prior to the screening visit,based on the allograft recipient's medical history.
Normal allograft function, defined respectively as:
liver function tests (ALT, GGT) for liver transplant recipients,
serum creatinine for kidney transplant recipients,
below the upper limit of normal (ULN) as defined by ranges from Harrison's Principles of Internal Medicine, 18th edition.
Receiving regular follow-up for a kidney or liver transplant by a local physician.
--Participants must be willing to allow the study team to contact and share medical information with this local physician.
and ability to sign informed consent.
You CAN'T join if...
Current malignancy requiring recent surgery, ongoing chemotherapy, or radiation;
Transplant of another organ;
Current drug or alcohol dependency;
Any medical condition that in the opinion of the principal investigator would interfere with safe completion of the trial; and
Inability to comply with the study visit schedule and required assessments.
University of California, San Franciscoaccepting new patients San Francisco, California, 94143, United States
Ann & Robert H. Lurie Children's Memorial Hospital of Chicagoaccepting new patients Chicago, Illinois, 60611, United States
Emory University School of Medicineaccepting new patients Atlanta, Georgia, 30324, United States
University of Pennsylvania Medical Centeraccepting new patients Philadelphia, Pennsylvania, 19104, United States
accepting new patients
National Institute of Allergy and Infectious Diseases (NIAID)